Trump Media and Technology Group Corp vs BIO-TECHNE Corp — how do they compare? Trump Media and Technology Group Corp trades at $8.29 (market cap $2.28B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 5× Trump Media and Technology Group Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and BIO-TECHNE Corp for 63 Days on average.
| DJT | TECH | |
|---|---|---|
Market Cap | $2.28B | $11.37B |
Volume | 4,132,682 | 3,153,511 |
Sector | Media | Health |
52-Week High | $17.07 | $72.61 |
52-Week Low | $7.06 | $43.31 |
Typical Hold Time | 17 Days | 63 Days |
Enterprise Value | $2.35B | $11.40B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.22, down 4.97% today, with a bearish technical signal (18 sell vs 6 buy indicators). The company shows severe financial distress with negative net income margin of -28,860.41% and ROE of -78.93% despite recent merger progress with TAE Technologies. Cash flow trends indicate significant investing outflows of $2.3B in 2025, partially offset by financing activities.
The outlook remains highly speculative with substantial execution risks from the TAE merger and persistent profitability challenges. While the merger offers potential long-term upside in fusion energy, current fundamentals and technical indicators suggest continued pressure. Investors face high volatility amid negative earnings and cash flow trends.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →